Macrophage death and defective inflammation resolution in atherosclerosis

Nature Reviews Immunology

Volumn 10, Issue 1, 2010, Pages 36-46

  Tabas, Ira ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS VACCINE; CYTOKINE; FINGOLIMOD; INTERLEUKIN 10; LIPOCORTIN 1; LIPOPROTEIN; LIPOXIN A; LIVER X RECEPTOR AGONIST; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RIMONABANT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VACCINE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CELL SURVIVAL; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; GENE MUTATION; HEART FAILURE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MEDIATOR RELEASE; MONOCYTE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGES; PHAGOCYTOSIS;

EID: 72949116358     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2675     Document Type: Review

References (120)

1. Serhan, C. N. et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325-332 (2007).
2. Lawrence, T. & Gilroy, D. W. Chronic inflammation: a failure of resolution? Int. J. Exp. Pathol. 88, 85-94 (2007).
3. Martinez, F. O., Helming, L. & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483 (2009).
4. [No authors listed]. 2007 NHLBI Morbidity and Mortality Chart Book. NHLBI Morbidity and Mortality Chartbook [online] http://www.nhlbi.nih. gov/resources/docs/cht-book.htm (2007).
5. Grundy, S. M. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89, 2595-2600 (2004).
6. Tabas, I., Williams, K. J. & Boren, J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116, 1832-1844 (2007).
7. Lusis, A. J. Atherosclerosis. Nature 407, 233-241 (2000).
8. Glass, C. K. & Witztum, J. L. Atherosclerosis: the road ahead. Cell 104, 503-516 (2001).
9. Tabas, I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25, 2255-2264 (2005).
10. Schrijvers, D. M., De Meyer, G. R., Herman, A. G. & Martinet, W. Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. Cardiovasc. Res. 73, 470-480 (2007).
11. Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N. & Chan, L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595-3606 (2008).
12. Randolph, G. J. Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr. Opin. Lipidol. 19, 462-468 (2008).
13. Virmani, R., Burke, A. P., Kolodgie, F. D. & Farb, A. Vulnerable plaque: the pathology of unstable coronary lesions. J. Interv. Cardiol. 15, 439-446 (2002).
14. Swirski, F. K. et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc. Natl Acad. Sci. USA 103, 10340-10345 (2006).
15. hi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117, 195-205 (2007).
16. Chawla, A. et al. PPAR-y dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Med. 7, 48-52 (2001).
17. Odegaard, J. I. et al. Macrophage-specific PPARy controls alternative activation and improves insulin resistance. Nature 447, 1116-1120 (2007).
18. Nofer, J. R. et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115, 501-508 (2007).
19. Laurat, E. et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104, 197-202 (2001).
20. Li, A. C. et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARa, p/6, and y. J. Clin. Invest. 114, 1564-1576 (2004).
21. Angeli, V. et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21, 561-574 (2004).
22. Llodra, J. et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl Acad. Sci. USA 101, 11779-11784 (2004).
23. Quah, B. J. & O'Neill, H. C. Maturation of function in dendritic cells for tolerance and immunity. J. Cell. Mol. Med. 9, 643-654 (2005).
24. Trogan, E. et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc. Natl Acad. Sci. USA 103, 3781-3786 (2006).
25. Mosser, D. M. & Zhang, X. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226, 205-218 (2008).
26. Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Rev. Immunol. 8, 349-361 (2008).
27. Willoughby, D. A., Moore, A. R., Colville-Nash, P. R. & Gilroy, D. Resolution of inflammation. Int. J. Immunopharmacol. 22, 1131-1135 (2000).
28. Serhan, C. N. et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15-23 (2009).
29. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med. 9, 213-219 (2003).
30. Huang, J. T. et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400, 378-382 (1999).
31. Li, Y. et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signalling mechanism. J. Biol. Chem. 283, 34833-34843 (2008).
32. Lingnau, M., Hoflich, C., Volk, H. D., Sabat, R. & Docke, W. D. Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum. Immunol. 68, 730-738 (2007).
33. Pinderski, L. J. et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90, 1064-1071 (2002).
34. Seljeflot, I., Hurlen, M., Solheim, S. & Arnesen, H. Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction. J. Thromb. Haemost. 2, 350-352 (2004).
35. Wahl, S. M., Swisher, J., Cartney-Francis, N. & Chen, W. TGF-β: the perpetrator of immune suppression by regulatory T cells and suicidal T cells. J. Leukoc. Biol. 76, 15-24 (2004).
36. Huynh, M. L., Fadok, V. A. & Henson, P. M. Phosphatidylserine- dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J. Clin. Invest. 109, 41-50 (2002).
37. Frutkin, A. D. et al. TGF-β1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein e-null mice. Arterioscler. Thromb. Vasc. Biol. 29, 1251-1257 (2009).
38. Mallat, Z. et al. Inhibition of transforming growth factor-β signalling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89, 930-934 (2001).
39. Lutgens, E. et al. Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22, 975-982 (2002).
40. Bahekar, A. A., Singh, S., Saha, S., Molnar, J. & Arora, R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am. Heart J. 154, 830-837 (2007).
41. Van Dyke, T. E. Resolution of inflammation-unraveling mechanistic links between periodontitis and cardiovascular disease. J. Dent. 37, S582-S583 (2009).
42. Peters-Golden, M. Putting on the brakes: cyclic AMP as a multipronged controller of macrophage function. Sci. Signal. 2, pe37 (2009).
43. Takayama, K. et al. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J. Biol. Chem. 277, 44147-44154 (2002).
44. Wall, E. A. et al. Suppression of LPS-induced TNF-α production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci. Signal. 2, ra28 (2009).
45. Babaev, V. R. et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab. 8, 492-501 (2008).
46. Marathe, C. et al. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. J. Biol. Chem. 281, 32197-32206 (2006).
47. Hong, C. & Tontonoz, P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18, 461-467 (2008).
48. Castrillo, A., Joseph, S. B., Marathe, C., Mangelsdorf, D. J. & Tontonoz, P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 278, 10443-10449 (2003).
49. Venkateswaran, A. et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proc. Natl Acad. Sci. USA 97, 12097-12102 (2000).
50. Tall, A. R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med. 263, 256-273 (2008).
51. Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604-7609 (2002).
52. Levin, N. et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25, 135-142 (2005).
53. Bradley, M. N. et al. Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE. J. Clin. Invest. 117, 2337-2346 (2007).
54. Rebe, C. et al. Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor-α pathway increases the clearance of apoptotic cells by human macrophages. Circ. Res. 105, 393-401 (2009).
55. Gonzalez, N. et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245-258 (2009).
56. Kockx, M. M. et al. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 97, 2307-2315 (1998).
57. Liu, J. et al. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 25, 174-179 (2005).
58. Boesten, L. S. et al. Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice. Atherosclerosis 88, 780-786 (2009).
59. Arai, S. et al. A role for the apoptosis inhibitory factor AIM/Spα/Api6 in atherosclerosis development. Cell Metab. 1, 201-213 (2005).
60. Wang, B. Y. et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation 99, 1236-1241 (1999).
61. Bhatia, V. K. et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am. J. Pathol. 170, 416-426 (2007).
62. Tabas, I. Apoptosis and plaque destabilization: the role of macrophage apoptosis induced by cholesterol. Cell Death. Differ. 11, S12-S16 (2004).
63. Zinszner, H. et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 12, 982-995 (1998).
64. Li, G. et al. Role of ERO1α-mediated stimulation of inositol 1, 4, 5-triphosphate receptor activity in endoplasmic reticulum stress-induced apoptosis. J. Cell Biol. 186, 783-792 (2009).
65. Timmins, J. M. et al. Calcium/calmodulin-dependent protein kinase II links endoplasmic reticulum stress with Fas and mitochondrial apoptosis pathways. J. Clin. Invest. 119, 2925-2941 (2009).
66. Seimon, T. & Tabas, I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J. Lipid Res. 50, S382-S387 (2009).
67. DeVries-Seimon, T. et al. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J. Cell Biol. 171, 61-73 (2005).
68. Seimon, T. A., Obstfeld, A., Moore, K. J., Golenbock, D. T. & Tabas, I. Combinatorial pattern recognition receptor signalling alters the balance of life and death in macrophages. Proc. Natl Acad. Sci. USA 103, 19794-19799 (2006).
69. Rosenfeld, M. E. et al. Animal models of spontaneous plaque rupture: the holy grail of experimental atherosclerosis research. Curr. Atheroscler. Rep. 4, 238-242 (2002).
70. Feng, B. et al. Niemann-Pick C heterozygosity confers resistance to lesional necrosis and macrophage apoptosis in murine atherosclerosis. Proc. Natl Acad. Sci. USA 100, 10423-10428 (2003).
71. Lim, W. S. et al. STAT1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation 117, 940-951 (2008).
72. -/- mice lacking CHOP. Cell Metab. 9, 474-481 (2009).
73. Manning-Tobin, J. J. et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler. Thromb. Vasc. Biol. 29, 19-26 (2009).
74. Liang, C. P. et al. Increased CD36 protein as a response to defective insulin signalling in macrophages. J. Clin. Invest. 113, 764-773 (2004).
75. Han, S. et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab. 3, 257-266 (2006).
76. Seimon, T. A. et al. Macrophage deficiency of p38α MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J. Clin. Invest. 119, 886-898 (2009).
77. Gargalovic, P. S. et al. The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 26, 2490-2496 (2006).
78. Myoishi, M. et al. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation 11 6, 1226-1233 (2007).
79. Sanson, M. et al. Oxidized low-density lipoproteins trigger endoplasmic reticulum stress in vascular cells: prevention by oxygen-regulated protein 150 expression. Circ. Res. 104, 328-336 (2009).
80. Henson, P. M., Bratton, D. L. & Fadok, V. A. Apoptotic cell removal. Curr. Biol. 11, R795-R805 (2001).
81. De Lorenzo, B. H. et al. Macrophage suppression following phagocytosis of apoptotic neutrophils is mediated by the S100A9 calcium-binding protein. Immunobiology 3 Aug 2009 (doi:10.1016/j.imbio.2009.05.013).
82. Mallat, Z. et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99, 348-353 (1999).
83. Schrijvers, D. M., De Meyer, G. R., Kockx, M. M., Herman, A. G. & Martinet, W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 1256-1261 (2005).
84. Ravichandran, K. S. & Lorenz, U. Engulfment of apoptotic cells: signals for a good meal. Nature Rev. Immunol. 7, 964-974 (2007).
85. Peter, C. et al. Migration to apoptotic "find-me" signals is mediated via the phagocyte receptor G2A. J. Biol. Chem. 283, 5296-5305 (2008).
86. Gardai, S. J. et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through transactivation of LRP on the phagocyte. Cell 123, 321-334 (2005).
87. Zhou, Z. New phosphatidylserine receptors: clearance of apoptotic cells and more. Dev. Cell 13, 759-760 (2007).
88. Boisvert, W. A. et al. Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size. Arterioscler. Thromb. Vasc. Biol. 26, 563-569 (2006).
89. Ait-Oufella, H. et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 115, 2168-2177 (2007).
90. -/- mice. Arterioscler. Thromb. Vasc. Biol. 28, 1421-1428 (2008).
91. Ait-Oufella, H. et al. Defective mer receptor tyrosine kinase signalling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 1429-1431 (2008).
92. Aprahamian, T. et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J. Exp. Med. 199, 1121-1131 (2004).
93. Libby, P. et al. Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol. 7, 330-335 (1996).
94. Li, Y. et al. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J. Biol. Chem. 281, 6707-6717 (2006).
95. Cui, D. et al. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J. Leukoc. Biol. 82, 1040-1050 (2007).
96. Sather, S. et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109, 1026-1033 (2007).
97. Komura, H., Miksa, M., Wu, R., Goyert, S. M. & Wang, P. Milk fat globule epidermal growth factor-factor VIII is downregulated in sepsis via the lipopolysaccharide-CD14 pathway. J. Immunol. 182, 581-587 (2009).
98. Zou, W. et al. Caenorhabditis elegans myotubularin MTM-1 negatively regulates the engulfment of apoptotic cells. PLoS. Genet. 5, e1000679 (2009).
99. Xu, W. et al. IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 107, 4930-4937 (2006).
100. Odegaard, J. I. et al. Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab. 7, 496-507 (2008).
101. Mukundan, L. et al. PPARδ senses and orchestrates clearance of apoptotic cells to promote tolerance. Nature Med. 15, 1266-1272 (2009).
102. Wilson, P. W., Castelli, W. P. & Kannel, W. B. Coronary risk prediction in adults (the Framingham Heart Study). Am. J. Cardiol. 59, 91G-94G (1987).
103. Aprahamian, T., Takemura, Y., Goukassian, D. & Walsh, K. Ageing is associated with diminished apoptotic cell clearance in vivo. Clin. Exp. Immunol. 152, 448-455 (2008).
104. Agrawal, A. et al. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signalling pathway. J. Immunol. 178, 6912-6922 (2007).
105. Liew, F. Y., Xu, D., Brint, E. K. & O'Neill, L. A. Negative regulation of Toll-like receptor-mediated immune responses. Nature Rev. Immunol. 5, 446-458 (2005).
106. Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972-978 (2007).
107. Liu, J. et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nature Med. 15, 940-945 (2009).
108. Zernecke, A. et al. Protective role of CXC receptor 4/ CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ. Res. 102, 209-217 (2008).
109. Saito, Y. et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200, 135-140 (2008).
110. Li, S. et al. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and its reversal by a fish oil diet. Circ. Res. 15 Oct 2009 (doi:10.1161/CIRCRESAHA.109.199570).
111. O'Sullivan, T. P. et al. Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J. Med. Chem. 50, 5894-5902 (2007).
112. Burstein, S. H. & Zurier, R. B. Cannabinoids, endocannabinoids, and related analogues in inflammation. AAPS J. 11, 109-119 (2009)
113. Dol-Gleizes, F. et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 29, 12-18 (2009).
114. Moreira, F. A. & Crippa, J. A. The psychiatric side-effects of rimonabant. Rev. Bras. Psiquiatr. 31, 145-153 (2009).
115. Maderna, P., Yona, S., Perretti, M. & Godson, C. Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac2-26. J. Immunol. 174, 3727-3733 (2005).
116. Wickline, S. A., Neubauer, A. M., Winter, P. M., Caruthers, S. D. & Lanza, G. M. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J. Magn. Reson. Imaging 25, 667-680 (2007).
117. Chen, Y. et al. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J. Immunol. 183, 1346-1359 (2009).
118. Hallett, J. M. et al. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol. Sci. 29, 250-257 (2008).
119. Rouleau, J. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am. J. Med. 11 8, S28-S35 (2005).
120. Strong, J. P., Malcom, G. T., Oalmann, M. C. & Wissler, R. W. The PDAY study: natural history, risk factors, and pathobiology. Pathobiological Determinants of Atherosclerosis in Youth. Ann. NY Acad. Sci. 811, 226-237 (1997).